Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 1Terminated 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 12Gastrointestinal 3Tumor-Agnostic 2Head & Neck 1Gynecologic 1CNS 1

Conditions

Neoplasms 44Neoplasm Metastasis 16Neoplasms, Unknown Primary 9Carcinoma 9Carcinoma, Squamous Cell 6Adenocarcinoma 2Neoplasms, Second Primary 1Neoplasm, Residual 1

Interventions

Oxaliplatin 14Gemcitabine 13Fluorouracil 11Leucovorin 9Capecitabine 9pembrolizumab 7Docetaxel 7Irinotecan 6Paclitaxel 5zolbetuximab 4regorafenib 4Trastuzumab 4Radiotherapy 4Pemetrexed 4S 1 (combination) 3Ramucirumab 3Nivolumab 3Drug Therapy 3Cisplatin 3Bevacizumab 3vandetanib 2tislelizumab 2sargramostim 2lenvatinib 2icotinib 2camrelizumab 2bemarituzumab 2apatinib 2Phlebotomy 2Esophagectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma × Carboplatin × Tumor-Agnostic × Clear all
NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

NCT00201734 2016-09-23

Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
57 enrolled 11 charts
Tumor-Agnostic

Adenocarcinoma, Neoplasms, Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡